Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Update

Dyadic International, Inc. (NASDAQ:DYAI) saw a large decrease in short interest in January. As of January 15th, there was short interest totalling 121,300 shares, a decrease of 22.7% from the December 31st total of 157,000 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average daily volume of 91,200 shares, the short-interest ratio is currently 1.3 days.

Dyadic International Price Performance

Shares of NASDAQ DYAI remained flat at $1.49 on Friday. The stock had a trading volume of 26,454 shares, compared to its average volume of 91,965. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15. Dyadic International has a 52 week low of $0.93 and a 52 week high of $2.67. The firm has a market cap of $44.09 million, a price-to-earnings ratio of -6.48 and a beta of 0.89. The company has a 50-day moving average price of $1.67 and a 200 day moving average price of $1.39.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. The business had revenue of $1.96 million during the quarter, compared to the consensus estimate of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same quarter last year, the company earned ($0.06) earnings per share. On average, sell-side analysts anticipate that Dyadic International will post -0.18 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Dyadic International in a report on Thursday, November 14th.

Institutional Trading of Dyadic International

Several hedge funds have recently added to or reduced their stakes in DYAI. Chapin Davis Inc. lifted its stake in Dyadic International by 2.5% during the third quarter. Chapin Davis Inc. now owns 868,301 shares of the biotechnology company’s stock valued at $903,000 after buying an additional 21,000 shares in the last quarter. Truist Financial Corp acquired a new position in Dyadic International in the 4th quarter worth approximately $428,000. Finally, Inlet Private Wealth LLC acquired a new position in Dyadic International in the 4th quarter worth approximately $52,000. Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.